Short-term safety profile of Intravitreal Ziv-Aflibercept

Retina

Volumn 36, Issue 6, 2016, Pages 1126-1131

  Chhablani, Jay ^a   Narayanan, Raja ^a   Mathai, Annie ^a   Yogi, Rohit ^a   Stewart, Michael ^b  

^a L V PRASAD EYE INSTITUTE   (India)

^b MAYO CLINIC   (United States)

Author keywords

aflibercept; AMD; anti VEGF; bevacizumab; CNV; ranibizumab; ziv aflibercept

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; AGE RELATED MACULAR DEGENERATION; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG SAFETY; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MALE; OPHTHALMOLOGICAL EQUIPMENT; OPTICAL COHERENCE TOMOGRAPHY DEVICE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL ACUITY CHART; AGED; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84949908751     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000913     Document Type: Article

References (24)

1. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.e1121.
2. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117: 2146-2151.
3. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-Treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-2299.
4. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
5. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121:2247-2254.
6. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014;121:202-208.
7. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Eng J Med 2011;364:1897-1908.
8. Available at: http://www.asrs.org/pat-survey/pat-survey-Archive. Accessed July 6, 2015.
9. Lux A, Llacer H, Heussen FM, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322.
10. Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Nonresponders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013;97:1443-1446.
11. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
12. Pinheiro-Costa J, Costa JM, Beato JN, et al. Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice. Ophthalmologica 2015;233:155-161.
13. Ehlken C, Jungmann S, Bohringer D, et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 2014;28:538-545.
14. Patel A, Sun W. Ziv-Aflibercept in metastatic colorectal cancer. Biologics 2014;8:13-25.
15. Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-Aflibercept in macular disease. Br J Ophthalmol 2015; 99:1055-1059.
16. McCulloch DL, Marmor MF, Brigell MG, et al. ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 2015;130:1-12.
17. Marmor MF, Martin LJ, Tharpe S. Osmotically induced retinal detachment in the rabbit and primate. Electron miscoscopy of the pigment epithelium. Invest Ophthalmol Vis Sci 1980;19: 1016-1029.
18. Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-Aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 2014;98:i11-i16.
19. de Oliveira Dias JR, Badaro E, Novais EA, et al. Preclinical investigations of intravitreal ziv-Aflibercept. Ophthalmic Surg Lasers Imaging Retina 2014;45:577-584.
20. Del Carpio JC, Moustafa MTM, Ramirez CA, et al. Effects of ranibizumab, bevacizumab, aflibercept, and ziv-Aflibercept on cultured human retinal Muller cells. Poster presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 3-8, 2014; Orlando, FL.
21. de Oliveira Dias JR, Xavier CO, Maia A, et al. Intravitreal injection of ziv-Aflibercept in patient with refractory agerelated macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2015;46:91-94.
22. Fine HF, Roth DB, Shah SP, et al. Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina 2015;35:681-686.
23. Hahn P, Chung MM, Flynn Jr. H.W., et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol 2015;133:421-426.
24. Goldberg RA, Shah CP, Wiegand TW, et al. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol 2014; 158:733-737.e731.